Quantcast

Vansen Pharma Inc. appoints Ali Moghaddam to its Board of Advisors

March 6, 2014

LAS VEGAS, March 6, 2014 /PRNewswire/ – Vansen Pharma Inc. [OTCQB: VNSN] is pleased to announce the appointment of Mr. Ali Moghaddam to its
Board of Advisors. Mr. Moghaddam is an accomplished pharmaceutical
executive with over 25 years of experience in both Canada and the U.S.,
having played a transformational role with companies such as Bristol-
Myers Squibb Canada, Linson Pharma Inc. (generic business unit of BMS),
Allergan Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group). He
brings a proven track record of hands-on leadership within the life
sciences field, in the areas of Product Life Cycle Management, Sales,
Business Development, Marketing, and Finance.

Accomplishments:

Mr. Moghaddam is currently the Vice President of Sales (Canada) for
Actavis Inc., (NYSE: ACT), a global, integrated specialty pharmaceutical company focused on
developing, manufacturing and distributing generic, brand and
biosimilar products. Prior to Actavis, he was the Vice President of
Business Development and Commercial Operations, (North America) at
Merus Labs International Inc. (NASDAQ:MSLI-TSX:MSL).

Mr. Moghaddam was also a key member of Linson Pharma Inc., Bristol-Myers
Squibb’s (NYSE:BMY) Pharmacy group, where he orchestrated the launch of generic
Pravastatin (Lin Pravastatin). Mr. Moghaddam is a CPA and CMA
(Chartered Professional Accountant and Certified Management Account) and holds Bachelors of Commerce and
Science degrees from Concordia University in Montreal.

About Vansen Pharma Inc.

Vansen Pharma Inc. is a specialty pharmaceutical company focused on
broad therapeutic areas that are anticipated to grow and present an
opportunity for major expansion. Vansen will expand its commercial
presence by adding complimentary products through in-licensing,
co-promotion and acquisitions, resulting in a comprehensive product
portfolio. With its US based sales force, Vansen can better serve the
increasing healthcare needs of patients and enhance growth. Vansen’s
current product portfolio of anti-infectives, including Factive®,
Spectracef® and Cefditoren Pivoxil®, provides a strong and stable
revenue base from which to grow and expand our company. Our experienced
management team is aggressively pursuing acquisitions of accretive
specialty products, including legacy drugs and cash flow positive
healthcare companies. We look forward to executing our growth strategy
and creating lasting shareholder value for our investors.

Cautionary Statement

Certain statements contained in this press release may constitute
“forward-looking statements” within the meaning of Section 21E (i) (1)
of the United States Securities Exchange Act of 1934. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Vansen’s actual results
to be materially different from any future results expressed or implied
by these statements. Such statements include but are not limited to,
that Vansen will expand its commercial presence by adding complimentary
products through in-licensing, co-promotion and acquisitions, resulting
in a comprehensive product portfolio, or that Vansen’s current product
portfolio will provide a strong and stable revenue base from which to
grow and expand the company. Such factors include the following:
general economic and business conditions, changes in demand for
Vansen’s products, changes in competition, the ability of Vansen to
integrate acquisitions or complete future acquisitions, interest rate
fluctuations, currency exchange rate fluctuations, dependence upon and
availability of qualified personnel and changes in government
regulation. In light of these and other uncertainties, the
forward-looking statements included in this press release should not be
regarded as a representation by Vansen that Vansen’s plans and
objectives will be achieved. These forward-looking statements speak
only as of the date of this press release, and we undertake no
obligation to update or revise the statements.

SOURCE Vansen Pharma Inc.


Source: PR Newswire



comments powered by Disqus